GMP Cell Therapy Consumables Market Size & Growth | 2028

The GMP cell therapy consumables market is expected to grow from US$ 11,031.25 million in 2021 to US$ 59,985.89 million by 2028; it is estimated to grow at a CAGR of 27.5% from 2022 to 2028.

The GMP cell therapy consumables market is segmented on the basis of product, cell therapy, process, end use, and regions. The report offers insights and in-depth analysis of the market, emphasizing various parameters such as dynamics, trends, and opportunities of the market and competitive landscape analysis of leading market players across various regions. It also includes the impact analysis of COVID–19 pandemic across the regions.

Market Insights

Rise in Research & Development and Drug Discovery Drive Market Growth

Drug discovery is a long process that comprises various steps such as early discovery, preclinical phase, clinical phase, and regulatory approval. The process tremendously involves the use of cell therapy consumables to achieve the desired results. According to the World Health Organization, ~10 million deaths due to cancer were recorded in 2020, and the most common cancers are breast, lung, colon, rectum, and prostate cancers. Various research studies have shown positive outcomes of drugs that can effectively treat cancer, neurological disorders, autoimmune disorders, and other chronic disorders. Therefore, the rising prevalence of chronic disorders propels the demand for research and development (R&D) activities.

Moreover, numerous biotechnology companies operating in the market are collaborating with each other to accelerate R&D activities on a global level. For instance, in October 2022, Century Therapeutics and Bristol Myers Squibb announced the research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cells (“iPSC”) derived, engineered natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors. Additionally, the rising demand for personalized and regenerative medicine has further boosted the growth of the cell therapy consumables market. An increase in drug discovery and R&D requires good manufacturing practices, and GMP consumables are required to obtain desired results from these activities. Thus, an increase in research & development activities, along with a surge in drug discovery, has increased the use of GMP cell therapy consumables.

GMP Cell Therapy Consumables Market -

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

GMP Cell Therapy Consumables Market: Strategic Insights

Market Size Value in	US$ 11,031.25 Million in 2021
Market Size Value by	US$ 59,985.89 Million by 2028
Growth rate	CAGR of 27.5% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2021

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Product-Based Insights

Based on product, the GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins, and others. In 2021, the kits segment held the largest market share. However, the growth factors/cytokines and interleukins segment are anticipated to register the highest CAGR in the market during 2022–2028. Reagents and supplements specifically designed for cell culture allow the growth and propagation of a wide spectrum of cell types under controlled conditions. TheraPEAK Products include an array of GMP buffers and reagents dedicated to the creation and development of cell and gene therapies. They are mainly produced in ISO: 13485 plants, such that these GMP solutions for cell and gene therapy are used by various customers in numerous clinical applications. There can be various types of molecular biology reagents that are GMP compliant in nature and mainly used in academics and clinical settings.

GMP Cell Therapy Consumables Market, by Product – 2021–2028

Cell Therapy-Based Insights

Based on cell therapy, the GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. In 2021, the T-cell therapy segment held the largest share of the market. However, the market in the NK cell therapy segment is expected to grow at the fastest rate during the forecast period. Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy used to treat certain types of cancer, especially blood cancer or leukemia. The therapy capitalizes the power of immune system protecting against the infections and illnesses by destroying harmful invaders, such as viruses and bacteria. Various research and clinical trials on CAR T-cell therapy are being conducted for cancer treatment. For instance, in January 2022, a new CAR T-cell therapy was developed by University College London (UCL) researchers. Phase-I clinical trials of this therapy carried out at UCL Hospitals (UCLH) concluded that this therapy has fewer toxic effects and is durable. Such increasing clinical trials of CAR T-cell therapy are surging the demand for GMP cell therapy consumables.

Process-Based Insights

Based on process, the GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. In 2021, the cell collection and characterization/sorting and separation segment held the largest share of the market. However, the GMP cell therapy consumables market in the cryopreservation segment is expected to grow at the fastest rate during the forecast period. Cell characterization is crucial for understanding the intrinsic factors involved in cellular proliferation, function, and overall process. Cells are sorted and separated based on these characteristics. Companies are building the GMP compliant cell sorter to avoid contamination during the process. For instance, Miltenyi Biotec sells MACSQuant Tyto Cell Sorter, a sterile and GMP compliant multiparametric cell sorting in a closed cartridge system. The company also provides a certificate of analysis (CoA), certificate of origin (CoO), and product information files (PIF) for the regulatory approval of cell manufacturing protocols.

End Use-Based Insights

Based on end use, the GMP cell therapy consumables market is segmented into clinical, commercial, and research. In 2021, the clinical segment held the largest share of the market. Also, the GMP cell therapy consumables market in the same segment is expected to grow at the fastest rate during the forecast period. In clinical use, cell therapy research is carried out on people to evaluate medical, surgical, or behavioral intervention of a particular therapy. Clinical trials are expanding due to the rising prevalence of chronic disorders, , increasing biologics, and rising number of contract research organizations undertaking clinical studies. Various cell therapies are expected to achieve market authorization in the coming years. According to a Nature article, 2,073 active cell therapy agents were in the pipeline in April 2021, which was 572 more than the 2020 update.

The GMP cell therapy consumables market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio across the world and meet the growing demand. Inorganic growth strategies witnessed in the market are partnerships and collaborations. These growth strategies have allowed the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help strengthen the company’s customer base and increase its product portfolio.

• In January 2021, Sartorius signed a strategic collaboration with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC). The collaboration advanced the scale-up of hMSC manufacturing for regenerative medicine. RoosterBio and Sartorius created a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems alongside Sartorius’s single-use manufacturing technologies, process control software, and cell analysis tools of hMSC final product manufacturing.
• In September 2020, Bio-Techne Corporation opened an ~61,000 square foot state-of-the-art Good Manufacturing Practices (GMP) manufacturing facility. Located in St. Paul, MN, the new facility is dedicated to support large-scale production of GMP-grade materials, which are an essential component for many immuno-oncology and regenerative medicine cell and gene-modified therapy workflows. This facility helps the company meet current and future demand for the GMP-grade reagents that are necessary to support the rapidly growing cell therapy market.

GMP Cell Therapy Consumables Market - Company Profiles

• Sartorius AG                             
• Thermo Fisher Scientific Inc         
• Miltenyi Biotec BV & Co KG          
• Bio-Techne Corp                        
• Corning Inc                               
• FUJIFILM Irvine Scientific Inc        
• Lonza Group AG                        
• BPS Bioscience Inc                     
• Merck KGaA                              
• Global Life Sciences Solutions USA LLC.